T1	Participants 33 93	predict survival in patients with advanced renal cell cancer
T2	Participants 761 808	416 patients, 362 were included in the analysis
T3	Participants 1441 1479	pre-treated patients with advanced RCC
T4	Participants 1535 1622	stratification of patients using these markers in future clinical trials is recommended
